

<!--StartFragment-->RESULT 7

AEK16520

ID AEK16520 standard; protein; 235 AA.

XX

AC AEK16520;

XX

DT 16-NOV-2006 (first entry)

XX

DE Human anti-M-CSF antibody (8.10.3F), light chain.

XX

KW monoclonal antibody; light chain; 8.10.3F; neoplasm; inflammation;

KW cardiovascular disease; atherosclerosis; sepsis; asthma;

KW autoimmune disease; osteoporosis; rheumatoid arthritis; osteoarthritis;

KW cancer; cytostatic; antiinflammatory; cardiovascular-gen.;

KW antiarteriosclerotic; antibacterial; immunosuppressive; antiasthmatic;

KW osteopathic; antiarthritic; antirheumatic.

XX

OS Homo sapiens.

XX

PN WO2006096489-A2.

XX

PD 14-SEP-2006.

XX

PF 02-MAR-2006; 2006WO-US007553.

XX

PR 08-MAR-2005; 2005US-0659765P.

XX

PA (PHAA) PHARMACIA & UPJOHN CO LLC.

XX

PI Devalaraja M, Fedechko R;

XX

DR WPI; 2006-627406/65.

DR

N-PSDB; AEK16519.

XX

PT Composition useful for treating e.g. neoplasia disorder and inflammatory

PT diseases comprises antibodies which bind to human macrophage-colony

PT stimulating factor; and has reduced levels of endotoxin.

XX

PS Claim 1; SEQ ID NO 4; 80pp; English.

XX

CC The invention relates to a composition comprises at least one antibody

CC that binds to human macrophage-colony stimulating factor (M-CSF). The

CC composition is free of endotoxin. The antibody comprises an amino acid

CC sequence that is at least 90% identical to the light chain sequence given

CC as SEQ ID NO:4 in the specification, and an amino acid sequence that is

CC at least 90% identical to the heavy chain sequence given as SEQ ID NO: 2

CC the specification. Also described is a method of purification of a

CC monoclonal IgG antibody and reducing endotoxin content in a composition

CC by: contacting the antibody or the composition with an affinity

CC chromatography resin that binds to the antibody, eluting the antibody

CC from the affinity chromatography resin to form an affinity chromatography

CC eluent containing the antibody, contacting the affinity chromatography

CC eluent with an ion-exchange resin that binds to the antibody, and eluting

CC the antibody from the ion-exchange resin. The antibody is an isolated

CC human monoclonal IgG2 anti-M-CSF antibody (preferably having the heavy

CC and light chain amino acid sequences of antibody 8.10.3F). The

CC composition of the invention is useful for the treatment of M-CSF-

CC mediated disorders, including neoplasia disorders, inflammatory

CC disorders, cardiovascular disorders, atherosclerosis, sepsis, asthma,

CC autoimmune diseases, osteoporosis, rheumatoid arthritis, osteoarthritis,

CC and cancers. The composition is almost free of endotoxin. The anti-M-CSF

CC antibody exhibits both species and molecule selectivity for M-CSF that is
CC at least 100 times greater than its selectivity for granulocyte-
CC macrophage (GM)-CSF or G-CSF. This sequence represents the light chain of
CC human anti-M-CSF antibody, 8.10.3F.
XX
SQ Sequence 235 AA;

Query Match 93.3%; Score 686.5; DB 1; Length 235;
Best Local Similarity 94.4%; Pred. No. 4.7e-41;
Matches 135; Conservative 3; Mismatches 4; Indels 1; Gaps 1;

Qy 1 METPAQLLFLLLLWLPD TTGEIVLTQSPG TSLSPGERATLSCRASQSVASAYLAWYQQK 60
|||||

Db 1 METPAQLLFLLLLWLPD TTGEFVLTQSPG TSLSPGERATLSCRASQSVSSSYLAWYQQK 60

Qy 61 PGQAPRL LIYGASSRATDIPHRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGT SALLTF 120
|||||

Db 61 PGQAPRL LIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSP-LTF 119

Qy 121 GGGTKVEIKRTVAAPSVFIFPPS 143
|||||

Db 120 GGGTKVEIKRTVAAPSVFIFPPS 142

<!--EndFragment-->